Key Developments: Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

29.24USD
12:06pm EDT
Price Change (% chg)

$-0.76 (-2.53%)
Prev Close
$30.00
Open
$30.07
Day's High
$30.07
Day's Low
$28.64
Volume
287,900
Avg. Vol
1,066,943
52-wk High
$101.00
52-wk Low
$26.25

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aegerion Pharmaceuticals, Inc reaffirms FY 2014 revenue guidance - Conference Call
Thursday, 15 May 2014 03:00pm EDT 

Aegerion Pharmaceuticals, Inc:Expects FY 2014 net product sales to be between $180 million and $200 million.  Full Article

Aegerion Pharmaceuticals Inc lowers FY 2014 revenue outlook
Tuesday, 6 May 2014 04:15pm EDT 

Aegerion Pharmaceuticals Inc:Expects FY 2014 global net product sales of between $180 -$200 mln, revised from the prior range of between $190 - $210 mln.FY 2014 revenue of $200 mln - Thomson Reuters I/B/E/S.  Full Article

Pomerantz LLP files a class action against Aegerion Pharmaceuticals, Inc. and certain officers
Friday, 14 Mar 2014 03:11pm EDT 

Pomerantz LLP:Files class action lawsuit against Aegerion Pharmaceuticals, Inc and certain officers.Class action, filed in United States District Court, District of Massachusetts, is on behalf of all persons or entities who purchased or acquired Aegerion securities between Mar. 15, 2012 and Jan. 9, 2014.Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about company's business, operations, and prospects.  Full Article

Aegerion Pharmaceuticals, Inc reaffirms FY 2014 revenue guidance
Wednesday, 26 Feb 2014 07:00am EST 

Aegerion Pharmaceuticals, Inc:Reaffirms FY 2014 guidance.Expects FY 2014 global net product sales of between $190 mln and $210 mln.FY 2014 revenue of $206 mln - Thomson Reuters I/B/E/S.  Full Article

Pomerantz LLP announces the filing of class action against Aegerion Pharmaceuticals Inc
Friday, 14 Feb 2014 05:30pm EST 

Pomerantz LLP:Says it has filed a class action lawsuit against Aegerion Pharmaceuticals, Inc. and certain of its officers.Says the class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Aegerion securities between Mar 15, 2012 and Jan 9, 2014, both dates inclusive (Class Period).Says the complaint alleges that throughout the class period, defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects.Says specifically, defendants made false and/or misleading statements and/or failed to disclose to Aegerion investors that: the company marketed its drugs in violation of the FDCA.Says as a result, the company faced heightened regulatory scrutiny by the FDA and other governmental bodies.Says and as a result of the foregoing, Aegerion's statements were materially false and misleading at all relevant times.  Full Article

Health Canada approves Aegerion Pharmaceuticals Inc' JUXTAPID capsules for treatment of homozygous familial hypercholesterolemia
Tuesday, 11 Feb 2014 08:00am EST 

Aegerion Pharmaceuticals Inc:Says that Health Canada has granted a Notice of Compliance approving JUXTAPID.Says Health Canada has granted JUXTAPID as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce low-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia.  Full Article

Law Offices of Howard G. Smith announces a class action lawsuit has been filed against Aegerion Pharmaceuticals, Inc.
Wednesday, 29 Jan 2014 08:04am EST 

Law Offices of Howard G. Smith:Says a class action lawsuit has been filed on behalf of all purchasers of Aegerion Pharmaceuticals, Inc. securities between Mar. 15, 2012 and Jan. 9, 2014.Says the complaint, filed in the United States District Court for the District of Massachusetts, alleges that Aegerion's marketing practices during the Class Period were in violation of the Food, Drug, and Cosmetic Act (FDCA).Says defendants made false and misleading statements or failed to disclose to Aegerion investors that the company marketed its drugs in violation of the FDCA. On Jan. 10.Says Aegerion received a subpoena from the U.S. Department of Justice requesting documents regarding its marketing and sale of Juxtapid.  Full Article

Aegerion Pharmaceuticals Inc announces class action litigation against Aegerion Pharmaceuticals, Inc
Tuesday, 28 Jan 2014 09:00am EST 

The law firm of Lieff Cabraser Heimann & Bernstein, LLP:Says a class action litigation has been brought on behalf of all purchasers of the securities of Aegerion Pharmaceuticals, Inc. between Mar. 15, 2012 and Jan. 9.Says the action alleges that throughout the Class Period, defendants made false and/or misleading statements and failed to disclose material adverse facts about Aegerion`s business, operations, and prospects.  Full Article

Bernstein Liebhard LLP files class action against Aegerion Pharmaceuticals, Inc
Thursday, 16 Jan 2014 01:23pm EST 

Bernstein Liebhard LLP:Says that a class action has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers (the Class) of securities of Aegerion Pharmaceuticals, Inc during the period of March 15, 2012 and Jan. 9.Says the Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects.  Full Article

Aegerion Pharmaceuticals Inc narrows FY 2013 revenue guidance to a range in line with analysts' estimates; gives FY 2014 revenue guidance in line with analysts' estimates
Thursday, 9 Jan 2014 05:00pm EST 

Aegerion Pharmaceuticals Inc:Sees FY 2013 net product sales of between $48 and $49 million, exceeding the company's initial FY 2013 revenue guidance of between $15 and $25 million, and in line with the company's recent guidance of between $45 and $50 million.Sees FY 2014 net product sales to be between $190 and $210 million.FY 2013 revenue $49 million-- Thomson Reuters I/B/E/S Estimates.FY 2014 revenue $204 million-- Thomson Reuters I/B/E/S Estimates.  Full Article

Search Stocks